CMPXCompass Therapeutics, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $0
- 100% YoY
- Operating margin
- —
- EBITDA
- −$73M
- 29% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$35M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $850K | $0 | 100% |
| Operating income | −$82M | −$42M | −$50M | −$57M | −$73M | 29% |
| Net income | −$82M | −$39M | −$42M | −$49M | −$66M | 35% |
| Operating cash flow | −$20M | −$34M | −$41M | −$45M | −$49M | 9.6% |
| Capex | $2M | $212K | $30K | $44K | $25K | 43% |
| Stock-based comp | $4M | $5M | $6M | $9M | $8M | 2.2% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $21K · 2
- Open-market sells, 12 mo
- $0 · 0
- Net
- $21K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 344 | — |
| FY2024 | — | — | 93 | — |